Mixed review for Biotronik's absorbable stent
January 30, 2013 by MassDevice staff
Biotronik touted positive early findings from a 1st-in-man trial of its absorbable metal stent, but researchers say the device need isn't as efficient as it could be.
German medical device maker Biotronik touted early findings from a 1st-in-man study of its Dreams absorbable drug-eluting stent, with researchers reporting a mixed bag of findings for the device.
The Dreams stent proved safe at 1 year following the procedure, but wasn't up to par with some rival devices, researchers noted.
- Show paged
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Rising healthcare costs not directly tied to medical technology, according to study
- CareFusion may be weighing 2 very different deals
- Medical Devices: What does it really mean to be disruptive?
- Smarter strategic moves bode well for Wright Medical
- The IRS, NSA, and Justice Department scandals and what they mean for HIPAA
- A Father's Day remembrance
- What I'd tell the graduating medical school class of 2013
- Silencing immune attacks in type 1 diabetes
- Eucomed guidance clarifies RoHS compliance for medical device companies
- How to simplify consents
Navigation
NEWS
Yale study of Medtronic's Infuse shows it's equivalent to bone graft, but studies were biased
A pair of independent analyses of patient-level data commissioned by a Yale University open data...
J&J's Synthes unit wins $16M ruling in patent fight with Globus Medical
A Delaware jury sides with Johnson & Johnson's DePuy-Synthes subsidiary in a patent spat over 3...
Aneurysm: Covidien touts pivotal study on Pipeline embolization device
Results of pivotal study on Covidien subsidiary eV3's Pipeline cerebral aneurysm device, published in...
ForSight Vision5 gets new CEO, closes $9.3M funding round
Delphi Ventures' John Maroney joins ForSight Vision5 as president, CEO & Director as the...
